Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Perspectives on the Ependymoma

Chemotherapy in Recurrent Ependymoma

Siffert J. · Allen J.C.

Author affiliations

Division of Pediatric Neurology, Department of Neurology, Beth Israel Medical Center, New York, N.Y., USA

Related Articles for ""

Pediatr Neurosurg 1998;28:314–319

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Perspectives on the Ependymoma

Published online: September 24, 1998
Issue release date: June 1998

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE

Abstract

Surgical resection with or without radiation therapy confers long-term remission in approximately half of the patients newly diagnosed with ependymoma. Chemotherapy has a limited role in the management of ependymoma. In newly diagnosed infants, chemotherapy is utilized as an attempt to defer radiation. The use of chemotherapy in older children has provided no conclusive benefit. The largest experience with chemotherapy in ependymoma has been in children with recurrent disease. In this section, we will analyze the principal institutional and cooperative group phase I, phase II, and phase III clinical trials utilizing single-agent and multiagent chemotherapy in patients with recurrent ependymoma. In addition, future directions relating to novel medical oncologic therapies will also be discussed.


References

  1. Healey E, Barnes P, Kupsky W, Scott R: The prognostic significance of postoperative residual tumors in ependymoma. Neurosurgery 1991;28:666–672.
  2. Nazar G, Hoffman H, Becker L, Jenkin D, Humphreys R, Hendrick E: Infratentorial ependymomas in childhood: Prognostic factors and treatment. J Neurosurg 1990;72:408–417.
  3. Dohrmann G, Farwell J, Flannery J: Ependymomas and ependymoblastomas in children. J Neurosurg 1976;45:273–283.
  4. Mork S, Lokn A: Ependymoma. A follow-up study of 101 cases. Cancer 1977;40:907–915.
  5. Pierre-Kahn A, Hirsch J, Roux F, Renier D, Sainte-Rose C: Intracranial ependymomas in childhood. Survival and functional results of 47 cases. Child’s Brain 1983;10:145–156.
  6. Cohen M, Duffner P: Brain Tumors in Children, ed 2. New York, Raven, 1994.
  7. Goldwein J, Corn B, Finlay J, Packer R: Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991;67:2766–2771.
  8. Kovalic J, Flaris N, Grigsby P, Pirkowski M, Simpson J, Roth K: Intracranial ependymoma: Long term outcome, patterns of failure. J Neurooncol 1993;15:125–131.
  9. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL: Adjuvant chemotherapy of childhood posterior fossa ependymoma: Cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: A Childrens Cancer Group study. Med Pediatr Oncol 1996;27:8–14.
  10. Weitman S, Ochoa S, Sullivan J, Shuster J, Winick N, Pratt C, Vietti T, Harris M: Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 1997;19:187–191.
  11. Wilson C, Guttin P, Boldrey E, Crafts D, Levin V, Enot K: Single-agent chemotherapy of brain tumors. Arch Neurol 1976;33:739–744.
    External Resources
  12. Allen JC, Hancock C, Walker R, Tan C: PCNU and recurrent childhood brain tumors. J Neurooncol 1987;5:241–244.
    External Resources
  13. Walker R, Allen J: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 1988;6:62–66.
    External Resources
  14. Bertolone S, Baum E, Krivit W, Hammond G: A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Group. J Neurooncol 1989;7:5–11.
    External Resources
  15. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD Hammond GD: Carboplatin in childhood brain tumors. A Children’s Cancer Study Group phase II trial. Cancer 1990;66:2465–2469.
  16. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Norris D, Ragab AH, Mahoney DH, Whitehead M, Kun LE: Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992;10:249–256.
  17. Allen JC, Packer RJ, Bleyer A: Recombinant interferon beta: A phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:783–788.
    External Resources
  18. Heideman RL, Packer RJ, Reaman GH, Allen JC, Lange B, Horowitz ME, Steinberg SM, Gillespie A, Kovnar EH, Balis FM, Poplack DG: A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993;72:271–275.
  19. Abrahamsen T, Lange B, Packer R, Venzon D, Allen J, Craig C, Patronas N, Katz D, Goldwein J, DeLaney T, Reaman G, Perilongo G, Phillips P, Oldfield E, Poplack D, Horowitz M: A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol 1995;17:134–139.
    External Resources
  20. Needle MN, Mollowy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, Sutton L, Phillips PC: Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28–32.
  21. Friedman H, Oakes W: The chemotherapy of posterior fossa tumors in childhood. J Neurooncol 1987;5:217–229.
    External Resources
  22. van Eys J, Baram T, Cangir A, Bruner J, Martinez-Prieto J: Salvage chemotherapy for recurrent primary brain tumors in children. J Pediatr 1988;113:601–606.
    External Resources
  23. Corden B, Strauss L, Killmond T, Carson B, Wharam M, Kumar A, Piantadose S, Robb P, Phillis P: Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neurooncol 1991;11:57–63.
  24. Chastagner P, Kalifa C, Gentet J, Doz F: Phase II study of cyclophosphamide (CTX) and etoposide (VP-16) in children with recurrent brain tumors (abstract 434). Proc ASCO 1992;11:153.
  25. Heideman R, Kuttesch J, Stewart C, Meyer W, Bowman L, Furman W, Gajjar A, Avery L, Pratt C: A phase I trial of a fixed systemic exposure (AUC) of carboplatin with continuous infusion topotecan in pediatric solid tumors. Proc ASCO 1995;14:A1430.
  26. Mahoney DH, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster J, Friedman H: High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study. J Clin Oncol 1996;14:382–388.
    External Resources
  27. Graham ML, Herndon JE II, Casey JR, Chaffee S, Giocci GH, Drischer JP, Kurtzberg J, Laughling MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS: High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814–1823.
    External Resources
  28. Grill J, Kalifa C, Doz F, Schoepfer C, Sainte-Rose C, Couanet D, Terrier-Lacombe TJ, Valteau-Couanet D, Hartmann O: A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. Pediatr Neurosurg 1996;25:7–12.
    External Resources
  29. Chou PM, Sanz CR, Tomita T, Reyes-Mugica M: Ependymomas in children express the multidrug resistance gene: Immunohistochemical and molecular biologic study. Pediatr Pathol Lab Med 1996;16:551–561.

Article / Publication Details

First-Page Preview
Abstract of Perspectives on the Ependymoma

Published online: September 24, 1998
Issue release date: June 1998

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.